标题/作者	年份
Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range T Battelino, T Danne, RM Bergenstal, SA Amiel, R Beck, T Biester, E Bosi, ... Diabetes care 42 (8), 1593-1603	2019
Review of methods for detecting glycemic disorders M Bergman, M Abdul-Ghani, RA DeFronzo, M Manco, G Sesti, ... Diabetes research and clinical practice 165, 108233	2020
Utilizing the ambulatory glucose profile to standardize and implement continuous glucose monitoring in clinical practice ML Johnson, TW Martens, AB Criego, AL Carlson, GD Simonson, ... Diabetes technology & therapeutics 21 (S2), S2-17-S2-25	2019
Ever-increasing insulin-requiring patients globally SK Garg, AH Rewers, HK Akturk Diabetes technology & therapeutics 20 (S2), S2-1-S2-4	2018
Glucose time in range, time above range, and time below range depend on mean or median glucose or HbA1c, glucose coefficient of variation, and shape of the glucose distribution D Rodbard Diabetes technology & therapeutics 22 (7), 492-500	2020
Respective contributions of glycemic variability and mean daily glucose as predictors of hypoglycemia in type 1 diabetes: are they equivalent? L Monnier, A Wojtusciszyn, N Molinari, C Colette, E Renard, D Owens Diabetes Care 43 (4), 821-827	2020
Glucose variability: how does it work? VV Klimontov, OV Saik, AI Korbut International journal of molecular sciences 22 (15), 7783	2021
Defining high glycemic variability in type 1 diabetes: comparison of multiple indexes to identify patients at risk of hypoglycemia AM Gómez, DC Henao, A Imitola Madero, LB Taboada, V Cruz, ... Diabetes technology & therapeutics 21 (8), 430-439	2019
Glucose variability and diabetes complications: Risk factor or biomarker? Can we disentangle the “Gordian Knot”? L Monnier, C Colette, D Owens Diabetes & Metabolism 47 (3), 101225	2021
Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open‐label, active‐controlled, 12‐week study (STABLE II study) SH Kwak, YC Hwang, JC Won, JC Bae, HJ Kim, S Suh, EY Lee, S Lee, ... Diabetes, Obesity and Metabolism 22 (2), 173-181	2020
Engineering digital biomarkers of interstitial glucose from noninvasive smartwatches B Bent, PJ Cho, M Henriquez, A Wittmann, C Thacker, M Feinglos, ... NPJ Digital Medicine 4 (1), 89	2021
A review of research progress on glycemic variability and gestational diabetes W Yu, N Wu, L Li, H OuYang, M Qian, H Shen Diabetes, Metabolic Syndrome and Obesity, 2729-2741	2020
Greater daily glucose variability and lower time in range assessed with continuous glucose monitoring are associated with greater aortic stiffness: The Maastricht Study YD Foreman, WPTM van Doorn, NC Schaper, MMJ van Greevenbroek, ... Diabetologia 64 (8), 1880-1892	2021
A retrospective in‐depth analysis of continuous glucose monitoring datasets for patients with hepatic glycogen storage disease: Recommended outcome parameters for glucose management F Peeks, IJ Hoogeveen, RL Feldbrugge, R Burghard, F de Boer, ... Journal of Inherited Metabolic Disease 44 (5), 1136-1150	2021
Glycaemic variation is a predictor of all-cause mortality in the Veteran Affairs Diabetes Trial JJ Zhou, J Koska, G Bahn, P Reaven Diabetes and Vascular Disease Research 16 (2), 178-185	2019
Critical reappraisal of the time-in-range: alternative or useful addition to glycated hemoglobin? L Heinemann, G Freckmann, D Müller-Wieland, M Kellerer Journal of Diabetes Science and Technology 14 (5), 922-927	2020
Long‐term glycemic control and glucose variability assessed with continuous glucose monitoring in a pediatric population with type 1 diabetes: determination of optimal sampling duration C Piona, M Marigliano, E Mozzillo, A Franzese, A Zanfardino, D Iafusco, ... Pediatric Diabetes 21 (8), 1485-1492	2020
Glucose variability and risk of hepatocellular carcinoma in patients with diabetes: a nationwide population-based study JJ Yoo, EJ Cho, K Han, SS Heo, BY Kim, DW Shin, SJ Yu Cancer Epidemiology, Biomarkers & Prevention 30 (5), 974-981	2021
Quality of glycemic control: assessment using relationships between metrics for safety and efficacy D Rodbard Diabetes technology & therapeutics 23 (10), 692-704	2021
Role of composite glycemic indices: a comparison of the comprehensive glucose pentagon across diabetes types and hba1c levels S Rama Chandran, R A. Vigersky, A Thomas, LL Lim, J Ratnasingam, ... Diabetes technology & therapeutics 22 (2), 103-111	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。